Fig 1.
Western blot analysis of XB130 in MMNK1, KKU-100, KKU-213C, KKU-213A and KKU-023 cell lines, with β-actin as a loading control.
Fig 2.
Effects of siXB130 on proliferation, motility and invasiveness of KKU-213A cell line.
A): The expressions of XB130 (130 kDa), E-cadherin (~135 kDa), vimentin (~54 kDa), Akt (~60 kDa), pAkt (~60 kDa) in siXB130 and scramble groups measured by western blotting, with β-actin as a loading control. B): MTT assays of the scramble and siXB130 treated cells. C): Hematoxylin-staining invasive cells from cell invasion assays of the scramble and siXB130 treated cells. D): Graphical represents numbers of invasive cells from cell invasion assays. E): Hematoxylin staining migrated cells from cell migration assays. F): Graphical represents numbers of migrating cells from cell migration assays. The asterisk (*) indicates statistical significance at P<0.05 and asterisks (***) indicates statistical significance at P < 0.001.
Fig 3.
XB130 expression patterns in: A) normal bile duct; intensity = 48, B) hepatocyte; intensity = 72 and C) CCA intensity = 220 analyzed by IHC.
The scale bar equals 50 μm.
Table 1.
Relationship between XB130 expression and clinicopathologic features of CCA patients.
Table 2.
Univariate analysis (Cox’s proportional hazards model) for overall survival of CCA patients.
Table 3.
Multivariate analysis (Cox’s proportional hazards model) for overall survival of CCA patients.
Table 4.
Univariate and multivariate analyses (logistic regression model) of factor correlated with lymph node metastasis (N1).